Harvard Bioscience, Inc. Form 8-K Filing

Harvard Bioscience, Inc. filed a Form 8-K on March 17, 2026, to disclose corporate updates. The company has appointed new executive leadership, with John Duke becoming CEO in July 2025 and Mark Frost permanently serving as CFO since March 2026. The company also announced a debt refinancing, extending maturity to 2029 and reducing annual debt service by $3 million, alongside a $7.5 million investment in convertible notes by BroadOak. The Board of Directors has been expanded with new appointments. Strategic consolidation includes streamlining the production footprint and improving manufacturing efficiency through the phased closure of the Holliston, MA plant, expected to yield significant adjusted EBITDA improvements in 2027 and 2028. Harvard Bioscience is also sharpening its strategic focus on Translational Science products, announced in February 2026. The filing also includes a corporate slide presentation (Exhibit 99.1) providing business updates and financial information, including non-GAAP financial measures.